RxDoctor Payments Data

Roma Patel, MD

Infectious Disease · Santa Ana, CANPI 1740523406

Payments from drug & device makers

$2,168in general payments, 2019–2025

Across 72 payments — averaging $30.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$616
  • Shionogi Inc$532
  • Gilead$530
  • La Jolla Pharmaceutical Company$196
  • Ferring Pharmaceuticals Inc.$145
  • Viiv Healthcare Company$58
  • plus $91 from 3 others

What the payments were for

  • Food & beverage$2,13999%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,168 in reported general payments places this provider in the 65th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$234,668
Medicare patients
532
Services billed
2,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala74$357,086
Daptomycin52$24,528
ErtapenemErtapenem Sodium54$20,493
MicafunginMicafungin Sodium21$11,516
Vancomycin Hcl39$4,699
CeftriaxoneCeftriaxone Sodium62$3,357
Fluconazole32$1,452
Cefazolin Sodium27$1,145
Doxycycline Hyclate41$1,010
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$770
Cephalexin42$742
Cefdinir17$417
Cefadroxil11$261
Amoxicillin28$249
Metronidazole11$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$530$357,08674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 856 infectious disease providers in California.

Other infectious disease in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →